Veradermics, Inc (MANE): Total Liabilities
$9.16M
As of 2025-12-31
$12.12M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.16M | +94.1% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $4.72M | n/a | 2026-03-30, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Veradermics, Inc (MANE) | 2025-12-31 | $9.16M | +94.1% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $52.56M | -56.6% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $20.27M | -15.3% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $14.52M | -18.6% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $119.41M | +123.3% |
| XBiotech Inc. (XBIT) | 2025-12-31 | $9.73M | -42.2% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $134.59M | +71.4% |
| Boundless Bio, Inc. (BOLD) | 2025-12-31 | $58.41M | +4.7% |
| Larimar Therapeutics, Inc. (LRMR) | 2025-12-31 | $67.76M | +138.5% |
Compare MANE, CTMX, OVID, WHWK side by side · Screen every company in Pharmaceutical Preparations ↗